Blood test may boost colorectal cancer screening in underserved communities
NCT ID NCT06929481
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether offering a blood test (cell free DNA) alongside standard stool tests and colonoscopy increases colorectal cancer screening rates among people who are not up-to-date with screening. The trial enrolls 340 adults aged 45-75 at a health center serving low-income and minority groups. Participants are randomly assigned to receive either standard screening options or expanded options that include the blood test, and researchers will compare how many complete screening within 60 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cell free DNA (cfDNA) blood test
- What this could lead to
- If successful, this could show that offering a simple blood test increases colorectal cancer screening rates among groups who currently face barriers, helping reduce health disparities.
- What could go wrong
- This is a small, early-stage pragmatic trial focused on screening completion, not cancer detection or survival. The blood test is less sensitive for advanced polyps than colonoscopy, so it may miss some precancerous growths.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Family Health Centers of San Diego, Logan Heights site
San Diego, California, 92113, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Why are more younger adults getting colorectal cancer? a national study digs into the data
- Can a common laxative beat the standard prep for colon cancer screening?
- Could a simple water trick help more doctors screen for colon cancer?
- New drug combo aims to boost response in Hard-to-Treat colorectal cancer
- First-in-Class cancer drug targets Hard-to-Treat tumors
- New pill targets Hard-to-Treat cancers with a specific gene mutation